Publications by authors named "J Wencel"

Claim this Profile
O
One-Day Brentuximab-Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma.
H Moatti, P Brice, M-C Laroque, R Di Blasi, J Wencel

Hematol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.
Loic Renaud, Juliette Wencel, Arnaud Pagès, Ahmad Al Jijakli, Hannah Moatti

Haematologica· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Internet Usage by Polish Patients With Multiple Sclerosis: A Multicenter Questionnaire Study.
Andrzej Potemkowski, Waldemar Brola, Anna Ratajczak, Marcin Ratajczak, Jacek Zaborski, Jacek Wencel

Interact J Med Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome.
Łukasz Jernas, Jacek Wencel, Andrzej Wiak, Marek Bieniek, Halina Bartosik-Psujek

PLoS One· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Effect of urinary tract infections on the effectiveness of the litholytic action of Debelysin].
A Gomuła, J Wencel, M Czaplicki

Pol Tyg Lek· January 1986

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis